Zhiqiang Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1374233/publications.pdf

Version: 2024-02-01

		1307594	1372567	
10	712	7	10	
papers	citations	h-index	g-index	
10	10	10	1264	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell, 2012, 21, 266-281.	16.8	374
2	Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood, 2012, 119, 1904-1914.	1.4	164
3	Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes and Cancer, 2013, 4, 82-90.	1.9	69
4	ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance. PLoS Genetics, 2014, 10, e1004414.	3.5	31
5	Sirtuins in Hematological Aging and Malignancy. Critical Reviews in Oncogenesis, 2013, 18, 531-547.	0.4	28
6	SIRT1 and LSD1 competitively regulate KU70 functions in DNA repair and mutation acquisition in cancer cells. Oncotarget, 2016, 7, 50195-50214.	1.8	26
7	CD150â° Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1. Stem Cells, 2015, 33, 3437-3451.	3.2	10
8	Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia. Communications Biology, 2022, 5, 396.	4.4	7
9	An aging mouse model of human chronic myeloid leukemia. Oncogene, 2021, 40, 3152-3163.	5.9	2
10	A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations. Methods in Molecular Biology, 2016, 1465, 149-157.	0.9	1